B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $125
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $110 to $125.
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $110 to $125.